<DOC>
	<DOCNO>NCT02062099</DOCNO>
	<brief_summary>Alzheimer 's disease ( AD ) common cause dementia elderly subject . AD characterize brain lesion like extracellular deposit ß-amyloïd protein senile plaque intracellular neurofibrillary tangle hyper-phosphorylated tau protein , associate loss neuron . The development disease biomarkers AD ( Tau , PhTau βamyloid dose cerebrospinal fluid , brain MRI , amyloid PET image fluorodeoxyglucose PET image ) identify pathophysiological process underlie cognitive impairment biomarkers , incorporate revised diagnosis guideline . Post-mortem human AD AD animal model study report inflammatory process also implicate neuropathology AD , upregulated level pro-inflammatory cytokine . In vivo visualization microglial activation become possible development molecular imaging ligand ( tracer ) use positron emission tomography ( PET ) . The translocator protein ( TSPO ) formerly know peripheral benzodiazepine receptor ( PBR ) , receptor locate outer membrane mitochondrion , upregulated neuroinflammation . So target TSPO radiolabeled ligand PET consider attractive biomarker neuroinflammation . The main aim pilot study quantify neuroinflammation , term fixation distribution [ 18F ] DPA-714 ( Binding Potential BP ) , study relationship amyloid load , measure [ 18F ] AV-45 ( Standard Uptake Values ratio ) cognitive decline .</brief_summary>
	<brief_title>PET Imaging Translocator Proteine Ligands ( TSPO ) With 18 F DPA-714 Biomarker NeuroInflammation Cognitive Decline ( NIDECO )</brief_title>
	<detailed_description>Molecular image microglial activation could help u document central inflammatory status study subject assist u design future research study particularly respect subject enrol clinical trial evaluate benefit specific therapy select group , example , monitor effect Aß immunization .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Criteria common participant : Signed informed consent Age ≥ 60 year old ( 6080 year old ) Native language : French Correct sensory ability ( hear aid accept ) perform test Affiliated social security system Criteria patient mild moderate Alzheimer disease define accord NINCDSADRDA { McKhann , 2011 # 408 } : MMS 20 25 Criteria amnestic MCI patient : Amnestic mildcognitive disorder evoke MA pre stage dementia { Dubois , 2010 # 273 , Dubois , 2007 # 42 ; Pertersen , 1999 # 21 , Albert , 2011 # 409 } old 60 year . Criteria patient isolated memory Complaint ( Without Cognitive Decline ) : MMS score ≥ 26 Normal performance age educational level</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>